Document is current

Any future updates will be listed below

Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Crossref DOI link: https://doi.org/10.1186/s13045-024-01620-y

Published Online: 2024-10-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark